导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.40% | 391/4773 |
| 近一周 | -0.47% | 199/5462 |
| 近一月 | 5.52% | 68/5421 |
| 近一季 | 6.95% | 229/5209 |
| 近半年 | 20.66% | 140/4920 |
| 近一年 | 23.50% | 315/4366 |
| 近两年 | 83.81% | 750/2954 |
| 近三年 | 110.40% | 109/2253 |
| 成立以来 | 62.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.79% 1448/4961 |
-0.01% 3229/5312 |
- - |
- - |
| 2025 | 32.78% 1160/4813 |
10.15% 336/3635 |
11.51% 174/4076 |
-0.52% 3926/4524 |
8.66% 232/4813 |
| 2024 | 36.72% 48/3463 |
3.88% 501/2808 |
15.12% 5/3014 |
4.20% 2903/3129 |
9.72% 311/3463 |
| 2023 | 0.96% 381/2656 |
-0.10% 1777/2280 |
6.97% 35/2385 |
-6.11% 1435/2515 |
0.63% 137/2655 |
| 2022 | 5.21% 20/2207 |
8.86% 13/1919 |
0.37% 1553/2016 |
-11.74% 572/2113 |
9.09% 239/2208 |
| 2021 | 4.28% 585/1822 |
13.40% 8/1255 |
-3.60% 1249/1330 |
-4.94% 752/1466 |
0.35% 1129/1822 |
| 2020 | -17.42% 1006/1250 |
-11.11% 818/1028 |
-3.73% 1039/1067 |
-16.15% 1136/1164 |
15.07% 236/1184 |
| 2019 | - - |
- - |
- - |
-4.53% 776/850 |
6.30% 631/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 泰康香港银行指数A VS. 长安沪深300非周期A(740101) |